Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
22,68 ^USD	-1,35 %		+6,38 %	-24,32 %

16.05.	Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
10.05.	ROCKET PHARMACEUTICALS, INC. : UBS bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe	29.05.
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy	29.05.
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	13.05.
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise	10.05.
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	10.05.
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy	10.05.
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
Rocket Pharmaceuticals: Q1 Earnings Snapshot	06.05.
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress	06.05.
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	16.04.
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	11.04.
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	02.04.
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02.04.
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02.04.
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	26.03.
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	26.03.
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	26.03.
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	26.03.
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05.03.
Rocket Pharmaceuticals Q4 Loss Narrows	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Andere Sprachen

Filter